Daxor Corporation (DXR)

Market Cap	40.41M
Revenue (ttm)	154,205
Net Income (ttm)	1.69M
Shares Out	4.84M
EPS (ttm)	0.35
PE Ratio	23.96
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,060
Open	8.15
Previous Close	8.14
Day's Range	8.15 - 8.35
52-Week Range	7.19 - 10.04
Beta	-0.51
Analysts	Strong Buy
Price Target	24.75 (+196.41%)
Earnings Date	n/a

About DXR

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 a...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1970
• Employees: 37
• Stock Exchange: NASDAQ
• Ticker Symbol: DXR
• Website: https://www.daxor.com

Financial Performance

In 2023, Daxor's revenue was $163,422, a decrease of -29.45% compared to the previous year's $231,641. Earnings were $280,640, a decrease of -94.58%.

Analyst Forecast

According to one analyst, the rating for DXR stock is "Strong Buy" and the 12-month stock price forecast is $24.75.

Price Target

$24.75

(196.41% upside)

Analyst Consensus: Strong Buy